Page 81 - MSU Digital Book
P. 81

ี
                                       ่
                                                                                    ำ
                                 ั
                                                                            ั
              5.  สมาคมปล้กี่ถ่่ายอวยวะแหงปรู้ะเทำศึไทำย. รู้ายงานข�อม้ลกี่ารู้ปล้กี่ถ่่ายอวยวะปรู้ะจาป พ.ศึ. 2561.
                  กี่รู้้งเทำพมหานครู้. สานกี่พมพกี่รู้้งเทำพเวช้สารู้.
                                    ั
                                       ิ
                                          ์
                                  ำ
              6.  Paul S. Primary causes of end-stage renal disease. [accessed 29 March 2020].
                  Available from:https://www.uspharmacist.com/article/primary-causes-of-
                  endstage-renal-disease.
              7.  Bia M, Adey DB, Bloom RD, Chan L, Kulkarni S, Tomlanovich S. KDOQI US
                  commentary on the 2009 KDIGO clinical practice guideline for the care of kidney
                  transplant recipients. Am J Kidney Dis. 2010;56:189-218.
              8.  Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical

                  practice guideline for the care of kidney transplant recipients. Am J Transplant.
                  2009;9 Suppl 3:S1-155.

              9.  Voora S, Adey DB. Management of kidney transplant recipients by general
                  nephrologists: core curriculum 2019. Am J Kidney Dis. 2019;73:866–79.
              10. Neuwirt H, Rudnicki M, Schratzberger P, Pirklbauer M, Kronbichler A, Mayer G.

                  Immunosuppression after renal transplantation. Memo - Mag Eur Med Oncol.
                  2019;12:216–21.

                               ่
                    ่
                    ้
                                     �
              11. กี่ลมนโยบื้ายแหงช้าต้ดานยา. บื้ญช้ยายาแผู้นปจจ้บื้น กี่ลม Drugs affecting the immune
                                   ิ
                                                                  ้
                                            ั
                                                             ั
                                                                  ่
                                               ่
                                                         ั
                                ึ
                  response. [เข�าถ่ง 29 ม่นาคม 2564]. จากี่: http://ndi.fda.moph.go.th/drug_national/
                                      ่
                  drugs_current ?p=บื้ัญช้ยาแผู้นปัจจ้บื้ัน&name=บื้ัญช้ยาแผู้นปัจจ้บื้ัน&g1=8&g2=2&g3=&g4=.
                                                              ่
              12. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Thymoglobulin
                  induction study group. Rabbit antithymocyte globulin versus basiliximab in renal
                  transplantation. N Engl J Med. 2006;355:1967-77.
              13. Wang K, Xu X, Fan M. Induction therapy of basiliximab versus antithymocyte
                  globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol.
                  2018;22:684-93.
              14. National Institute for Health and Care Excellence (NICE). Immunosuppressive
                  therapy for kidney transplant in adults. TA481. London: NICE; 2017.
              15. Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, et al.
                  Immunosuppressive therapy for kidney transplantation in adults: a systematic

                  review and economic model. Health Technol Assess. 2016;20:1-594.
              16. U.S. Food and Drug Administration. FDA approved drug products. [accessed 29

                  March 2020]. Available from: https://www.accessdata.fda. gov/scripts/cder/daf/.



              56
   76   77   78   79   80   81   82   83   84   85   86